This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 May;20(5):967-70.

doi: 10.1093/annonc/mdp206.

Hypertension as a surrogate marker for the activity of anti-VEGF agents

O Mir, S Ropert, J Alexandre, F Goldwasser

PMID: 19403940
DOI: 10.1093/annonc/mdp206

Free article

Comment

Hypertension as a surrogate marker for the activity of anti-VEGF agents

O Mir et al. Ann Oncol. 2009 May.

Free article

. 2009 May;20(5):967-70.

doi: 10.1093/annonc/mdp206.

Authors

O Mir, S Ropert, J Alexandre, F Goldwasser

PMID: 19403940
DOI: 10.1093/annonc/mdp206

No abstract available

PubMed Disclaimer

Comment on

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Scartozzi M, et al. Ann Oncol. 2009 Feb;20(2):227-30. doi: 10.1093/annonc/mdn637. Epub 2008 Oct 7. Ann Oncol. 2009. PMID: 18842611

Similar articles

Anti-VEGF Anticancer Drugs: Mind the Hypertension.
Katsi V, Zerdes I, Manolakou S, Makris T, Nihoyannopoulos P, Tousoulis D, Kallikazaros I. Katsi V, et al. Recent Adv Cardiovasc Drug Discov. 2014;9(2):63-72. doi: 10.2174/1574890110999150604114127. Recent Adv Cardiovasc Drug Discov. 2014. PMID: 26123049 Review.
Uncontrolled Hypertension and Oncology: Clinical Tips.
Kalaitzidis RG, Elisaf MS. Kalaitzidis RG, et al. Curr Vasc Pharmacol. 2017;16(1):23-29. doi: 10.2174/1570161115666170414121436. Curr Vasc Pharmacol. 2017. PMID: 28413967 Review.
Use of Antihypertensive Drugs in Neoplastic Patients.
Rizzoni D, De Ciuceis C, Porteri E, Agabiti-Rosei C, Agabiti-Rosei E. Rizzoni D, et al. High Blood Press Cardiovasc Prev. 2017 Jun;24(2):127-132. doi: 10.1007/s40292-017-0198-z. Epub 2017 Mar 30. High Blood Press Cardiovasc Prev. 2017. PMID: 28361339 Review.
Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Kruzliak P, Novák J, Novák M. Kruzliak P, et al. Am J Hypertens. 2014 Jan;27(1):3-13. doi: 10.1093/ajh/hpt201. Epub 2013 Oct 29. Am J Hypertens. 2014. PMID: 24168915 Review.
The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.
Thanigaimani S, Kichenadasse G, Mangoni AA. Thanigaimani S, et al. Curr Vasc Pharmacol. 2011 May;9(3):358-80. doi: 10.2174/157016111795495503. Curr Vasc Pharmacol. 2011. PMID: 20807189 Review.

See all similar articles

Cited by

Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.
Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Keefe D, et al. Oncologist. 2011;16(4):432-44. doi: 10.1634/theoncologist.2010-0271. Epub 2011 Mar 25. Oncologist. 2011. PMID: 21441297 Free PMC article. Review.
Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis.
Shibata K, Akasaki Y, Tokushige A, Nitta M, Kawasoe S, Kubozono T, Oda K, Kumagai K, Mawatari S, Ohishi M. Shibata K, et al. Hypertens Res. 2025 Apr;48(4):1542-1553. doi: 10.1038/s41440-025-02149-4. Epub 2025 Feb 18. Hypertens Res. 2025. PMID: 39966607 Free PMC article.
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules.
Grothey A, Galanis E. Grothey A, et al. Nat Rev Clin Oncol. 2009 Sep;6(9):507-18. doi: 10.1038/nrclinonc.2009.110. Epub 2009 Jul 28. Nat Rev Clin Oncol. 2009. PMID: 19636328 Review.
Treatment of bevacizumab-induced hypertension by amlodipine.
Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S, Billemont B, Knebelmann B, Goldwasser F. Mir O, et al. Invest New Drugs. 2012 Apr;30(2):702-7. doi: 10.1007/s10637-010-9549-5. Epub 2010 Sep 29. Invest New Drugs. 2012. PMID: 20878444
Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
Shah RR, Morganroth J, Shah DR. Shah RR, et al. Drug Saf. 2013 May;36(5):295-316. doi: 10.1007/s40264-013-0047-5. Drug Saf. 2013. PMID: 23620167 Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information